SOAT1 and Sezary syndrome: Given its mechanism of action targeting the JAK/STAT signaling pathway, the current evidence and its favorable side-effect profile compared to conventional chemotherapeutics, oclacitinib, and potentially other JAK inhibitors, may represent a viable therapeutic option for CETL in dogs, particularly in Sézary syndrome.